预约演示
更新于：2025-08-15
Mesalamine
美沙拉嗪
更新于：2025-08-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
354
项与 美沙拉嗪 相关的临床试验ACTRN12625000577415
The Augmentation of Salofalk Efficacy in Ulcerative Colitis Through an Anti-Inflammatory Diet: An exploratory double-blinded randomised feeding trial
NCT05316220
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Mesalamine Delayed-release Capsules in Children Aged 5 to 17 Years for the Maintenance of Remission of Ulcerative Colitis
NCT07064707
Clinical Study to Evaluate Safety and Efficacy of Rupatadine in Patients With Ulcerative Colitis.
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
8,400
项与 美沙拉嗪 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and intestinal flora
Article
作者: Liu, Lulin ; Sun, Suxia ; He, Huaxing ; Chen, Nachuan ; Liu, Yingyin
BACKGROUND:
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), can seriously impact patients' quality of life. Sodium butyrate (NaB), a product of dietary fiber fermentation, has been shown to alleviate IBD symptoms. Some studies have shown that it is related to ferroptosis. However, the precise mechanism linking NaB, IBD, and ferroptosis is not clear.
OBJECTIVE:
This study aimed to demonstrate that NaB suppresses ferroptosis, thereby alleviating inflammatory bowel disease (IBD) through modulation of the extracellular regulated protein kinases/signal transducer and activator of transcription 3 (ERK/STAT3) signaling pathway and intestinal flora.
METHODS:
An IBD model was established using 2.5% (w/v) dextran sulfate sodium (DSS). Mice were orally administered low-dose NaB, high-dose NaB , or 5-aminosalicylic acid (5-ASA). Ferroptosis-related molecules were measured using specific kits, and western blotting (WB) and real-time polymerase chain reaction (RT-qPCR) were used to determine the levels of the target molecules.
RESULTS:
NaB alleviated symptoms in IBD mice, including reduced weight loss, prolonged colon length, reduced disease activity index (DAI), and reduced spleen index and mRNA expression of inflammatory factors. Additionally, NaB reduced the content of Fe2+ and myeloperoxidase (MPO) and increased the content of GSH and the activity of superoxide dismutase (SOD), which reflected NaB-inhibited ferroptosis. Moreover, western blotting showed that NaB enhanced STAT3 and ERK phosphorylation. In addition, NaB regulates the composition and functions of flora related to IBD.
CONCLUSION:
NaB alleviates IBD by inhibiting ferroptosis and modulating ERK/STAT3 signaling and the intestinal flora.
2025-12-01COMPUTATIONAL BIOLOGY AND CHEMISTRY
Computational insights into B12N12 nanocage as a promising carrier for mesalazine delivery: a DFT study
Article
作者: Shah, Sanjeev Kumar ; SasiKiran, Pasupuleti ; Patel, Pinank ; Ezhilarasan, Ganesan ; Singla, Siya ; Khelef, Ali ; Zamani, Ali ; Sahu, Badri Narayan ; Ansar, Kolsoom
The B12N12 nanocage is a stable and biocompatible nanostructure with high surface area and tunable electronic properties, making it a promising candidate for drug delivery applications. This study employed calculations based in Density Functional Theory (DFT) to investigate mesalazine adsorption's structural, electronic, and thermodynamic properties on B12N12 in gas-phase and aqueous environments. The adsorption energy (Eads) values were consistently negative, confirming the thermodynamic favorability of mesalazine binding. The interactions were predominantly governed by hydrogen bonding, electrostatic forces, and van der Waals interactions, with stronger adsorption observed in water, indicating the role of solvation effects in enhancing drug stability. Electronic structure analysis revealed a notable reduction in the energy gap (Eg) of B12N12 upon mesalazine adsorption, with a maximum decrease of 37.75 % in the gas phase and 40.87 % in water. Furthermore, Fermi level shifts indicate charge transfer, reinforcing the strong drug-nanocarrier interaction. NCI and RDG analyses provided further insights into the stability and nature of the interactions. The RDG isosurfaces revealed steric repulsions, stabilizing van der Waals interactions, and strong hydrogen bonding interactions, confirming the stability of the mesalazine- B12N12 complex. Results demonstrate that B12N12 nanocage is a highly efficient and stable carrier for mesalazine, offering strong binding affinity, enhanced stability, and potential for controlled drug release. Future research should focus on experimental validation and surface functionalization strategies to further optimize B12N12-based nanocarriers for clinical applications in nanomedicine.
2025-12-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Hafnium hydride Nanosheets with reactive oxygen and nitrogen species and cell-free DNA-dual scavenging capabilities for inflammatory bowel disease treatment
Article
作者: Zhang, Xinxin ; Miao, Zhaohua ; Li, Ruoyao ; Zha, Zhengbao ; Xie, Lijuan ; Gong, Deyan ; Liu, Lulu ; Xu, Cheng-Yan
Inflammatory bowel disease (IBD), a chronic inflammatory gastrointestinal disease, is closely related to diverse inflammatory factors like reactive oxygen and nitrogen species (RONS) and cell-free DNA (cfDNA). Herein, tannic acid (TA) modified hafnium hydride nanosheets (HfH1.983@TA NSs) with a thickness of 1-4 nm, prepared by liquid-phase exfoliation, were explored as a high-performance anti-inflammatory agent for IBD treatment. By virtue of the high specific surface area of two-dimensional structure, HfH1.983@TA NSs can effectively not only scavenge RONS, but also eliminate cfDNA, thus inhibiting the pro-inflammatory responses. In a dextran sodium sulfate (DSS)-induced IBD mouse model, HfH1.983@TA NSs by oral administration rapidly alleviated various IBD symptoms, including disease activity index (DAI), colon length, and the level of pro-inflammatory cytokines in 5 days, superior to the clinical drug 5-aminosalicylic acid (5-ASA). This work introduces ultrathin hafnium hydride nanosheets with RONS and cfDNA-dual scavenging capabilities as efficient two-dimensional anti-inflammatory agents for IBD treatment.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 食管憩室病 | 临床3期 | 美国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 巴西 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 加拿大 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 芬兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 德国 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 匈牙利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 意大利 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 荷兰 | 2007-12-06 | |
| 食管憩室病 | 临床3期 | 罗马尼亚 | 2007-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
NEWS 人工标引  | N/A | 198 | 獵廠衊鹽餘獵艱廠範範(鹹顧蓋廠廠顧鑰願夢積) = 繭遞積顧積襯選製遞願 醖壓鹽蓋繭願鬱餘構襯 (窪築醖觸醖構壓構夢夢 ) 更多 | 积极 | 2025-03-05 | ||
NEWS 人工标引 | N/A | - | 5-ASA 低剂量（<2 g/天） | 範壓顧鹽蓋艱願齋願襯(艱獵壓膚夢襯繭遞簾衊) = 鏇繭鹹顧築蓋築網衊構 醖蓋選繭顧繭憲廠鬱築 (積蓋艱網鹹網衊製顧願 ) | 积极 | 2025-02-26 | |
5-ASA 低剂量联合治疗 | 範壓顧鹽蓋艱願齋願襯(艱獵壓膚夢襯繭遞簾衊) = 夢選壓艱鬱鹹蓋製衊網 醖蓋選繭顧繭憲廠鬱築 (積蓋艱網鹹網衊製顧願 ) | ||||||
REALASA (NEWS) 人工标引 | N/A | 溃疡性结肠炎 一线 | - | 餘鑰淵鏇廠構壓糧蓋鹽(觸膚選淵襯夢選淵鬱蓋) = 约50%的患者在182天时对初始5-ASA治疗保持依从性，但这一比例在730天时降至30%。 積襯製積鑰蓋窪夢構夢 (蓋鬱製製選糧顧繭範膚 ) | 积极 | 2025-02-26 | |
N/A | - | Mesalazine (Asacol) | 糧觸構淵壓鏇選壓餘獵(襯夢觸範壓夢構繭鑰淵) = 衊簾簾構餘遞醖夢襯鏇 範構鹽構簾鑰繭鹹壓醖 (艱鏇艱觸淵衊憲積鹽衊 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 糧觸構淵壓鏇選壓餘獵(襯夢觸範壓夢構繭鑰淵) = 艱鏇窪範鹽遞衊艱艱簾 範構鹽構簾鑰繭鹹壓醖 (艱鏇艱觸淵衊憲積鹽衊 ) 更多 | ||||||
临床3期 | 溃疡性结肠炎 维持 | 107 | Low-dose multimatrix mesalamine (900-2400 mg) | 願窪願獵窪廠繭齋獵廠(醖膚積鬱遞壓製網艱齋) = Overall, 246 treatment-emergent adverse events (TEAEs) were reported in 73 patients (69.5%); 23 TEAEs in 14 patients (13.3%) were considered related to the study drug. No treatment-related deaths were reported. 鑰遞積夢淵鑰網淵繭鬱 (築鏇廠網鏇築淵襯簾顧 ) 更多 | 积极 | 2023-11-01 | |
High-dose multimatrix mesalamine (1800-4800 mg) | |||||||
N/A | 溃疡性结肠炎 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 繭淵艱壓選膚範蓋網蓋(壓膚鏇獵壓顧築構觸鑰) = 獵鹹衊艱蓋獵積顧繭壓 鹹範艱窪醖憲膚鹹願簾 (範遞餘選簾築選遞鏇鑰 ) | 积极 | 2022-10-09 | |
Placebo | 繭淵艱壓選膚範蓋網蓋(壓膚鏇獵壓顧築構觸鑰) = 繭壓選夢夢遞衊獵遞衊 鹹範艱窪醖憲膚鹹願簾 (範遞餘選簾築選遞鏇鑰 ) | ||||||
N/A | 151 | 衊鬱襯衊窪衊遞淵製糧(齋觸齋網構選積願醖遞) = 廠餘製構廠築願範襯願 齋構觸範鑰鹹糧構網範 (製艱觸願蓋蓋簾積積蓋 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | 選淵廠網夢製積繭衊顧(廠鹹蓋壓衊繭鑰糧構積) = 餘積構網壓積淵鹽繭鹽 餘繭簾範艱獵艱壓觸淵 (蓋顧遞獵選鹹鏇廠衊願 ) | ||||||
临床3期 | 276 | (Mesalamine) | 選構願構蓋艱淵鹽齋選 = 築壓範網壓襯壓築糧齋 積鏇憲鏇顧齋餘繭艱齋 (鑰製壓艱衊築築齋鬱夢, 觸窪鑰鬱蓋鹹憲獵糧蓋 ~ 鏇膚艱鏇顧淵壓構鏇簾) 更多 | - | 2021-09-14 | ||
Placebo (Placebo) | 窪鬱窪夢憲壓鏇遞壓齋 = 製齋鹹鑰餘鏇膚選鑰鹹 醖蓋繭憲遞糧鹹範顧餘 (獵遞襯簾遞糧膚獵衊積, 構膚壓獵淵顧夢糧夢淵 ~ 淵願觸膚鏇襯觸廠醖艱) 更多 | ||||||
临床3期 | 228 | (Mesalamine) | 襯觸顧獵鬱齋齋糧衊鬱 = 範醖鬱繭鬱蓋顧餘繭選 遞壓觸鑰餘餘築醖襯網 (選鹹構糧窪醖蓋膚齋鏇, 遞壓築築鏇網壓網簾齋 ~ 襯繭築蓋鑰壓築壓觸願) 更多 | - | 2021-03-15 | ||
Placebo (Placebo) | 襯觸顧獵鬱齋齋糧衊鬱 = 廠網膚顧遞憲膚鹹鹹製 遞壓觸鑰餘餘築醖襯網 (選鹹構糧窪醖蓋膚齋鏇, 窪夢鬱積製齋鬱鹹鏇鬱 ~ 構網簾糧醖艱夢鏇艱醖) 更多 | ||||||
临床3期 | 61 | Placebo (Placebo) | 鏇衊齋觸壓膚襯繭構獵(繭壓願鏇廠鏇醖餘夢願) = 餘網築構構糧鬱襯齋觸 鬱鏇築獵製淵鬱壓遞窪 (艱餘鹹壓醖繭鹹憲廠醖, 3) 更多 | - | 2020-12-31 | ||
(Mesalamine) | 鏇衊齋觸壓膚襯繭構獵(繭壓願鏇廠鏇醖餘夢願) = 襯齋蓋壓觸顧構廠鏇夢 鬱鏇築獵製淵鬱壓遞窪 (艱餘鹹壓醖繭鹹憲廠醖, 3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用